Harmony Biosciences Holdings Inc(HRMY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 11.93 | EPS (ttm) | 3.09 | Insider Own | 13.8% | Shs Outstand | 58.1M | Perf Week | -1.89% |
| Market Cap | 2.14B | Forward P/E | 8.29 | EPS next Y | 12.44% | Insider Trans | -0.89% | Shs Float | 50.2M | Perf Month | -10.74% |
| Enterprise Value | 1.70B | PEG | 0.38 | EPS next Q | 1.11 | Inst Own | 95.55% | Short Float | 11.02% | Perf Quarter | 2.96% |
| Income | 0.18B | P/S | 2.23 | EPS this Y | 45.72% | Inst Trans | -3.28% | Short Ratio | 5.92 | Perf Half Y | 18.62% |
| Sales | 0.96B | P/B | 2.14 | EPS next 5Y | 22.07% | ROA | 14.61% | Short Interest | 5.53M | Perf YTD | -1.58% |
| Book/sh | 17.19 | P/C | 3.21 | EPS past 3/5Y | -3% - | ROE | 20.46% | 52W High | -15.31% ($43.49) | Perf Year | 21.75% |
| Cash/sh | 11.47 | P/FCF | 6.04 | Sales past 3/5Y | 25.64% 40.3% | ROIC | 15.93% | 52W Low | 42.19% ($25.90) | Perf 3Y | 88.2% |
| Dividend Est. | - | EV/EBITDA | 6.63 | EPS Y/Y TTM | -0.83% | Gross Margin | 72.94% | Volatility(W/M) | 6.35% 4.27% | Perf 5Y | -12.02% |
| Dividend TTM | - | EV/Sales | 1.77 | Sales Y/Y TTM | 24.25% | Oper. Margin | 24.03% | ATR (14) | 1.65 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.45 | EPS Q/Q | 88.57% | Profit Margin | 18.88% | RSI (14) | 40 | Recom | 1.75 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.48 | Sales Q/Q | 30.32% | SMA20 | -4.19% ($38.44) | Beta | 1.01 | Target Price | $48.25 |
| Payout | - | Debt/Eq | 0.22 | Earnings | 2026/11/4 | SMA50 | -7.43% ($39.79) | Rel Volume | 0.91 | Prev Close | $36.13 |
| Employees | 293 | LT Debt/Eq | 0.14 | EPS/Sales Surpr. | 33.85% 4.19% | SMA200 | 6.25% ($34.66) | Avg Volume(3M) | 0.94M | Price | $36.83 |
| IPO | 2020/8/19 | Option/Short | Yes/Yes | Trades | 8268 | Volume | 852,747 | Change | 1.94% |
A US biopharmaceutical company focused on developing and commercializing treatments for rare neurological disorders. The company has commercialized an oral therapy for sleep-wake disorders such as narcolepsy and is developing a follow-on pipeline targeting additional rare neurological and psychiatric conditions. Operating under a model that combines prescription growth of its commercial product with pipeline advancement, the company is establishing its footprint in the underserved neurological disorders market.
Over the past 1 year, roughly in the middle
15% below its 1-year high.
Traded about as much as usual. That is 91% of its average volume.
Next earnings report: November 4
8 days to go.
HRMY makes money exceptionally well
Of every $100 in sales, $24.03 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +45.7% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company expected to earn $100 next year, you would pay $829. Peers typically go for $2,544. Compared with its own 5-year average, it is 12% cheaper now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -12.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 95.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #94 of 594 in the industry
Based on market cap of $2B.
BHVN#91 Biohaven Ltd $2B PER - 
XNCR#92 Xencor Inc $2B PER - 
PGEN#93 Precigen Inc $2B PER - HRMY#94 Harmony Biosciences Holdings Inc $2B PER 11.9 
IMNM#95 Immunome Inc $2B PER - 
FAQ
What kind of company is HRMY?
HRMY belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of HRMY?
The market cap of HRMY is approximately $2.1B, ranking 1,970 within its sector.
What is the P/E ratio of HRMY?
HRMY has a P/E ratio of approximately 11.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for HRMY?
HRMY has recorded a 52-week high of $43.49 and a low of $25.90.
